Enhabit, Inc. (EHAB) Stock Analysis and Metrics

Enhabit

NYSE: EHAB

$13.80 ▲ +0.01 (+0.07%)

At close: May 14, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap706.56 Mn

P/E-642.33

P/S0.66

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)428.60 Mn

Revenue Growth (1y) (Qtr)1.89

Add ratio to table…

About

Enhabit, Inc. is a leading provider of home health and hospice services in the United States. The company delivers skilled medical care to patients in their homes, focusing on clinical excellence and cost-effective solutions. It operates across 34 states with a network of 249 home health and 117 hospice locations as of December 31, 2025.

Enhabit generates revenue primarily through Medicare and Medicare Advantage programs, which together accounted for 89.7% of its total net service revenue in 2025. Additional revenue comes from managed care plans, private insurers, Medicaid, and direct patient payments. The company’s services are reimbursed based on government-established rates and negotiated contracts with various payers.

Enhabit operates through the following segments: Home Health and Hospice.

• Home Health: This segment provides skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. For the year ended December 31, 2025, it served an average daily census of 41,786 patients and generated $813.8 million in net service revenue, representing 76.8% of Enhabit’s total. The segment focuses on reducing hospital readmissions and supporting recovery after acute illness or surgery.

• Hospice: This segment offers nursing care, pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement support to terminally ill patients and their families. In 2025, it maintained an average daily census of 3,985 patients and generated $246.2 million in net service revenue, or 23.2% of Enhabit’s total. The program emphasizes quality of life during end-of-life care.

Enhabit positions itself as a leading provider in the fragmented home health and hospice industries, leveraging scale, clinical quality, and technology to compete effectively. It differentiates itself through high patient satisfaction scores, lower-than-average hospital readmission rates, and strong performance in government quality ratings. The company benefits from its integrated service model and disciplined operational approach in a market undergoing shifts toward value-based care.

Enhabit serves elderly patients requiring skilled medical care at home, particularly those recovering from hospitalization or managing chronic conditions. Its hospice patients are individuals with terminal illnesses seeking comfort-focused care. The company also works closely with physicians, hospitals, and long-term care facilities that refer patients for its services.

Investment Thesis

▲ Bull case

Enhabit's hospice segment continues to demonstrate strong operational performance and profitability, which serves as a key growth engine and margin driver for the company. Hospice revenue increased 11% year-over-year in Q3 2024, driven by patient day growth and higher Medicare reimbursement rates, with same-store hospice census up 5% and average daily census rising 6.9% year-over-year. This growth is supported by improving referral conversion rates, which increased from 74.2% to 77.4% following the rollout of centralized admissions, and enhanced case management effectiveness, evidenced by visits in the last days of life being 53.2% higher than the national average. Hospice adjusted EBITDA increased $2.3 million or 29.9% year-over-year, reflecting significant operating leverage as cost per day remained flat despite volume growth. Management expects hospice volumes and revenues to grow at mid- to high-single digits in 2025, underpinned by the October 1, 2024 hospice reimbursement rate increase of approximately 4%, which is estimated to contribute $8 million in annual revenue based on current census. The recent appointment of Dale Clift as CEO, following Kinderhook Industries' acquisition, brings proven leadership experience in scaling home health and hospice organizations, including his prior role as CEO of Trilogy Home Healthcare, which he led to rapid growth before its 2023 acquisition. This leadership transition, combined with the incoming CFO Ryan Solomon with over 20 years of relevant experience, signals a strategic focus on executing operational improvements and capitalizing on favorable reimbursement trends to drive sustainable growth in the hospice segment, which remains underappreciated by the market given the company's overall flat to declining consolidated revenue narrative.
Enhabit's payor innovation strategy is creating a structural shift in its home health payer mix that is driving higher-margin growth and reducing reliance on traditional Medicare fee-for-service, yet this transition is not being fully valued by investors focused on near-term revenue declines. Non-Medicare home health admissions grew 20.1% year-over-year in Q3 2024, driving total admissions growth of 5.6%, with same-store admissions up 5.5%. Critically, 45% of non-Medicare home health visits are now covered by payor innovation contracts, up from just 19% a year ago, and 73% of total home health admissions combined are in either Medicare fee-for-service or payor innovation contracts—unchanged in Medicare fee-for-service share at 44% over the last three quarters but reflecting a significant shift toward higher-value contracts. These value-based arrangements typically provide higher reimbursement rates than standard Medicare Advantage and are designed to improve care quality while controlling costs. Despite declining recertifications in the home health segment—attributed to shorter-length-of-stay admissions from acute care facilities and payor mix changes in congregate living settings—the company is actively mitigating this by expanding and diversifying referral sources. The ongoing negotiations with UnitedHealthcare, while not yet finalized, are described as being "very close to coming to terms," and Enhabit has successfully replaced declining United census, with total payor home health census growing by 884 from August through October 2024 despite a United census decline of 1,022 patients. This demonstrates effective payer transition execution and reduces the perceived risk of the UnitedHealthcare notice. The market is underestimating the long-term margin expansion potential from this payer mix shift, as payor innovation contracts offer more stable, higher-reimbursement revenue streams that are less vulnerable to the periodic CMS home health payment rule pressures affecting traditional fee-for-service.
Enhabit is executing a disciplined cost optimization and profitability enhancement plan that is already yielding measurable results and is poised to deliver significant EBITDA expansion in 2025, yet the market remains focused on top-line pressures and overlooks the accelerating impact of these initiatives. Home office general and administrative expenses decreased $4.3 million year-over-year in Q3 2024, now representing 8.7% of consolidated revenue, reflecting successful cost controls and lower incentive compensation. The company expects to realize full run-rate savings from key restructuring initiatives in 2025, including care management department restructuring and leadership changes expected to generate $3 million in annual savings, with full benefit realized in 2025. Additionally, the transition from centralized to outsourced coding for all branches by end of fiscal Q1 2025 is anticipated to save $2 million per year, with $1.5 million realized in 2025. These actions are being taken amid ongoing CMS reimbursement pressure, with the final home health rule resulting in a net 0.5% payment increase—expected to add $2 million to $3 million annually to Medicare revenue base—after a previously feared larger cut was mitigated. The company's leverage ratio improved to 4.8 times, down for the third consecutive quarter, and available liquidity increased to approximately $94 million from $61 million at year-end, supported by strong free cash flow generation of approximately $59 million year-to-date through September 2024, with a conversion rate of 79%. The de novo strategy continues to be funded by EBITDA from prior-year new market entries, with three new locations opened in 2024, three pending CMS approval, and nine active projects, enabling low-capital geographic expansion. Hurricane impacts in Q3 and Q4 2024 are estimated to reduce fourth-quarter revenue and EBITDA by only $2 million, a relatively minor impact given the company's scale, and all affected branches have resumed operations. These cost-saving and efficiency initiatives, combined with favorable reimbursement trends and organic growth investments, are expected to drive meaningful EBITDA growth in 2025 that the market is not adequately pricing in, particularly as guidance for 2024 adjusted EBITDA was revised only modestly to $98 million to $102 million despite the headwinds, indicating resilience in the underlying business model.

Enhabit's hospice segment continues to demonstrate strong operational performance and profitability, which serves as a key growth engine and margin driver for the company. Hospice revenue increased 11% year-over-year in Q3 2024, driven by patient day growth and higher Medicare reimbursement rates, with same-store hospice census up 5% and average daily census rising 6.9% year-over-year. This growth is supported by improving referral conversion rates, which increased from 74.2% to 77.4% following the rollout of centralized admissions, and enhanced case management effectiveness, evidenced by visits in the last days of life being 53.2% higher than the national average. Hospice adjusted EBITDA increased $2.3 million or 29.9% year-over-year, reflecting significant operating leverage as cost per day remained flat despite volume growth. Management expects hospice volumes and revenues to grow at mid- to high-single digits in 2025, underpinned by the October 1, 2024 hospice reimbursement rate increase of approximately 4%, which is estimated to contribute $8 million in annual revenue based on current census. The recent appointment of Dale Clift as CEO, following Kinderhook Industries' acquisition, brings proven leadership experience in scaling home health and hospice organizations, including his prior role as CEO of Trilogy Home Healthcare, which he led to rapid growth before its 2023 acquisition. This leadership transition, combined with the incoming CFO Ryan Solomon with over 20 years of relevant experience, signals a strategic focus on executing operational improvements and capitalizing on favorable reimbursement trends to drive sustainable growth in the hospice segment, which remains underappreciated by the market given the company's overall flat to declining consolidated revenue narrative.
Enhabit's payor innovation strategy is creating a structural shift in its home health payer mix that is driving higher-margin growth and reducing reliance on traditional Medicare fee-for-service, yet this transition is not being fully valued by investors focused on near-term revenue declines. Non-Medicare home health admissions grew 20.1% year-over-year in Q3 2024, driving total admissions growth of 5.6%, with same-store admissions up 5.5%. Critically, 45% of non-Medicare home health visits are now covered by payor innovation contracts, up from just 19% a year ago, and 73% of total home health admissions combined are in either Medicare fee-for-service or payor innovation contracts—unchanged in Medicare fee-for-service share at 44% over the last three quarters but reflecting a significant shift toward higher-value contracts. These value-based arrangements typically provide higher reimbursement rates than standard Medicare Advantage and are designed to improve care quality while controlling costs. Despite declining recertifications in the home health segment—attributed to shorter-length-of-stay admissions from acute care facilities and payor mix changes in congregate living settings—the company is actively mitigating this by expanding and diversifying referral sources. The ongoing negotiations with UnitedHealthcare, while not yet finalized, are described as being "very close to coming to terms," and Enhabit has successfully replaced declining United census, with total payor home health census growing by 884 from August through October 2024 despite a United census decline of 1,022 patients. This demonstrates effective payer transition execution and reduces the perceived risk of the UnitedHealthcare notice. The market is underestimating the long-term margin expansion potential from this payer mix shift, as payor innovation contracts offer more stable, higher-reimbursement revenue streams that are less vulnerable to the periodic CMS home health payment rule pressures affecting traditional fee-for-service.
Enhabit is executing a disciplined cost optimization and profitability enhancement plan that is already yielding measurable results and is poised to deliver significant EBITDA expansion in 2025, yet the market remains focused on top-line pressures and overlooks the accelerating impact of these initiatives. Home office general and administrative expenses decreased $4.3 million year-over-year in Q3 2024, now representing 8.7% of consolidated revenue, reflecting successful cost controls and lower incentive compensation. The company expects to realize full run-rate savings from key restructuring initiatives in 2025, including care management department restructuring and leadership changes expected to generate $3 million in annual savings, with full benefit realized in 2025. Additionally, the transition from centralized to outsourced coding for all branches by end of fiscal Q1 2025 is anticipated to save $2 million per year, with $1.5 million realized in 2025. These actions are being taken amid ongoing CMS reimbursement pressure, with the final home health rule resulting in a net 0.5% payment increase—expected to add $2 million to $3 million annually to Medicare revenue base—after a previously feared larger cut was mitigated. The company's leverage ratio improved to 4.8 times, down for the third consecutive quarter, and available liquidity increased to approximately $94 million from $61 million at year-end, supported by strong free cash flow generation of approximately $59 million year-to-date through September 2024, with a conversion rate of 79%. The de novo strategy continues to be funded by EBITDA from prior-year new market entries, with three new locations opened in 2024, three pending CMS approval, and nine active projects, enabling low-capital geographic expansion. Hurricane impacts in Q3 and Q4 2024 are estimated to reduce fourth-quarter revenue and EBITDA by only $2 million, a relatively minor impact given the company's scale, and all affected branches have resumed operations. These cost-saving and efficiency initiatives, combined with favorable reimbursement trends and organic growth investments, are expected to drive meaningful EBITDA growth in 2025 that the market is not adequately pricing in, particularly as guidance for 2024 adjusted EBITDA was revised only modestly to $98 million to $102 million despite the headwinds, indicating resilience in the underlying business model.

▼ Bear case

Enhabit's home health segment continues to face structural headwinds from declining recertifications and unfavorable payer mix shifts that are undermining its core revenue base, despite management's emphasis on non-Medicare growth and payor innovation contracts as offsetting factors. Home health segment revenue decreased $9.9 million or 4.7% year-over-year in Q3 2024, primarily driven by declining recertifications, which management attributed to increased admissions from acute care facilities with shorter predictable lengths of stay and ongoing payer mix changes in congregate living settings. These settings typically yield higher recertification rates due to older, sicker patients with greater chronic illness burden, and their decline represents a fundamental shift in the patient mix that reduces long-term revenue sustainability. While non-Medicare admissions grew 20.1% year-over-year, this growth is coming from lower-acuity, shorter-length-of-stay patients that do not recertify at the same rate as traditional home health populations, limiting the segment's ability to generate recurring revenue episodes. Medicare fee-for-service admissions declined 2.5% sequentially from Q2 to Q3 2024, an improvement from the prior year's 4.7% decline but still indicative of persistent softness in the core Medicare base, with the 44% share of total home health admissions remaining unchanged over the last three quarters. The company's reliance on payor innovation contracts—while growing to 45% of non-Medicare visits—does not fully compensate for the loss of high-recertification Medicare fee-for-service volume, as these contracts often serve different patient populations with less predictable, episodic needs. Furthermore, the ongoing review and planned consolidation or closure of eight to ten underperforming branches by early 2025 signal that multiple locations are failing to generate acceptable returns, suggesting that the home health segment's underlying unit economics are deteriorating in certain markets, and the cost of remediation or exit may offset anticipated savings. The market may be ignoring the fact that recertification is a critical driver of home health revenue stability, and its persistent decline points to a deeper, industry-wide challenge that payor innovation alone cannot resolve in the near term.
Enhabit's hospice segment, while showing strong volume growth and margin expansion, faces increasing reimbursement and regulatory risks that could constrain future profitability, particularly as the benefits of the recent rate increase may be offset by broader policy shifts toward value-based care and site-neutral payment reforms. Although hospice revenue increased 11% year-over-year in Q3 2024 and adjusted EBITDA grew 29.9%, driven by patient day growth and a 4% Medicare reimbursement rate increase effective October 1, 2024 (estimated to add $8 million annually), the company remains vulnerable to potential changes in hospice payment methodology. The broader home health and hospice industry is under increasing scrutiny from policymakers concerned about fraud, overutilization, and rising Medicare expenditures, which could lead to future payment cuts or stricter eligibility requirements. Hospice faces specific risks from potential site-neutral payment proposals that would align reimbursement with care delivered in other settings, potentially reducing the financial incentive for home-based hospice care. Additionally, the segment's growth is dependent on maintaining referral conversion rates and case management effectiveness, which, while currently strong (with visits in the last days of life 53.2% above national average), could deteriorate if referral sources shift to competing providers or if operational execution falters during leadership transitions. The appointment of Dale Clift as CEO, while bringing operational experience, introduces execution risk during the integration phase under new ownership by Kinderhook Industries, and the company's focus on cost-saving initiatives like outsourcing and branch consolidations may inadvertently impact care quality or referral relationships if not managed carefully. The market may be overestimating the sustainability of hospice growth without adequately considering how evolving regulatory and payment models could compress margins or limit volume expansion in the coming years, especially if the current favorable rate environment proves temporary.
Enhabit's financial profile is being challenged by elevated leverage and uncertain free cash flow conversion, which could constrain its ability to fund growth initiatives and return capital to shareholders despite recent improvements in liquidity and debt paydown. Although the leverage ratio improved to 4.8 times—down for the third consecutive quarter—and available liquidity increased to approximately $94 million from $61 million at year-end, this level of leverage remains relatively high for a healthcare services provider, particularly given the company's exposure to reimbursement volatility and operational disruptions from natural disasters. The year-to-date free cash flow through September 2024 was approximately $59 million with a conversion rate of 79%, but management explicitly stated that the full-year conversion target remains at approximately 50%, indicating that the strong year-to-date performance is benefiting from temporary working capital timing advantages (such as accounts receivable and payroll timing) that are not expected to persist. This suggests that normalized free cash flow generation may be significantly lower than recent results imply, limiting the company's capacity to invest in de novo projects, pursue acquisitions, or return capital through buybacks or dividends. The guidance for 2024 free cash flow was set at $47 million to $55 million, reflecting a more conservative outlook that accounts for the normalization of working capital and the impact of hurricane-related disruptions. Furthermore, the company's suspension of financial guidance and earnings releases pending the proposed merger with Anchor Parent, LLC (affiliated with Kinderhook Industries) creates uncertainty about future financial performance and capital allocation priorities. If the merger proceeds, Enhabit may lose strategic autonomy, and any cost savings or operational improvements may be redirected toward satisfying parent company objectives rather than reinvestment in growth. The market may be ignoring the risk that high leverage, combined with uncertain and potentially declining free cash flow conversion, could limit financial flexibility and increase vulnerability to adverse reimbursement changes or operational setbacks, particularly if the expected synergies from the merger are delayed or fail to materialize.

Enhabit's home health segment continues to face structural headwinds from declining recertifications and unfavorable payer mix shifts that are undermining its core revenue base, despite management's emphasis on non-Medicare growth and payor innovation contracts as offsetting factors. Home health segment revenue decreased $9.9 million or 4.7% year-over-year in Q3 2024, primarily driven by declining recertifications, which management attributed to increased admissions from acute care facilities with shorter predictable lengths of stay and ongoing payer mix changes in congregate living settings. These settings typically yield higher recertification rates due to older, sicker patients with greater chronic illness burden, and their decline represents a fundamental shift in the patient mix that reduces long-term revenue sustainability. While non-Medicare admissions grew 20.1% year-over-year, this growth is coming from lower-acuity, shorter-length-of-stay patients that do not recertify at the same rate as traditional home health populations, limiting the segment's ability to generate recurring revenue episodes. Medicare fee-for-service admissions declined 2.5% sequentially from Q2 to Q3 2024, an improvement from the prior year's 4.7% decline but still indicative of persistent softness in the core Medicare base, with the 44% share of total home health admissions remaining unchanged over the last three quarters. The company's reliance on payor innovation contracts—while growing to 45% of non-Medicare visits—does not fully compensate for the loss of high-recertification Medicare fee-for-service volume, as these contracts often serve different patient populations with less predictable, episodic needs. Furthermore, the ongoing review and planned consolidation or closure of eight to ten underperforming branches by early 2025 signal that multiple locations are failing to generate acceptable returns, suggesting that the home health segment's underlying unit economics are deteriorating in certain markets, and the cost of remediation or exit may offset anticipated savings. The market may be ignoring the fact that recertification is a critical driver of home health revenue stability, and its persistent decline points to a deeper, industry-wide challenge that payor innovation alone cannot resolve in the near term.
Enhabit's hospice segment, while showing strong volume growth and margin expansion, faces increasing reimbursement and regulatory risks that could constrain future profitability, particularly as the benefits of the recent rate increase may be offset by broader policy shifts toward value-based care and site-neutral payment reforms. Although hospice revenue increased 11% year-over-year in Q3 2024 and adjusted EBITDA grew 29.9%, driven by patient day growth and a 4% Medicare reimbursement rate increase effective October 1, 2024 (estimated to add $8 million annually), the company remains vulnerable to potential changes in hospice payment methodology. The broader home health and hospice industry is under increasing scrutiny from policymakers concerned about fraud, overutilization, and rising Medicare expenditures, which could lead to future payment cuts or stricter eligibility requirements. Hospice faces specific risks from potential site-neutral payment proposals that would align reimbursement with care delivered in other settings, potentially reducing the financial incentive for home-based hospice care. Additionally, the segment's growth is dependent on maintaining referral conversion rates and case management effectiveness, which, while currently strong (with visits in the last days of life 53.2% above national average), could deteriorate if referral sources shift to competing providers or if operational execution falters during leadership transitions. The appointment of Dale Clift as CEO, while bringing operational experience, introduces execution risk during the integration phase under new ownership by Kinderhook Industries, and the company's focus on cost-saving initiatives like outsourcing and branch consolidations may inadvertently impact care quality or referral relationships if not managed carefully. The market may be overestimating the sustainability of hospice growth without adequately considering how evolving regulatory and payment models could compress margins or limit volume expansion in the coming years, especially if the current favorable rate environment proves temporary.
Enhabit's financial profile is being challenged by elevated leverage and uncertain free cash flow conversion, which could constrain its ability to fund growth initiatives and return capital to shareholders despite recent improvements in liquidity and debt paydown. Although the leverage ratio improved to 4.8 times—down for the third consecutive quarter—and available liquidity increased to approximately $94 million from $61 million at year-end, this level of leverage remains relatively high for a healthcare services provider, particularly given the company's exposure to reimbursement volatility and operational disruptions from natural disasters. The year-to-date free cash flow through September 2024 was approximately $59 million with a conversion rate of 79%, but management explicitly stated that the full-year conversion target remains at approximately 50%, indicating that the strong year-to-date performance is benefiting from temporary working capital timing advantages (such as accounts receivable and payroll timing) that are not expected to persist. This suggests that normalized free cash flow generation may be significantly lower than recent results imply, limiting the company's capacity to invest in de novo projects, pursue acquisitions, or return capital through buybacks or dividends. The guidance for 2024 free cash flow was set at $47 million to $55 million, reflecting a more conservative outlook that accounts for the normalization of working capital and the impact of hurricane-related disruptions. Furthermore, the company's suspension of financial guidance and earnings releases pending the proposed merger with Anchor Parent, LLC (affiliated with Kinderhook Industries) creates uncertainty about future financial performance and capital allocation priorities. If the merger proceeds, Enhabit may lose strategic autonomy, and any cost savings or operational improvements may be redirected toward satisfying parent company objectives rather than reinvestment in growth. The market may be ignoring the risk that high leverage, combined with uncertain and potentially declining free cash flow conversion, could limit financial flexibility and increase vulnerability to adverse reimbursement changes or operational setbacks, particularly if the expected synergies from the merger are delayed or fail to materialize.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password